Globus Medical Raises Full-Year EPS Guidance

Globus Medical (NYSE: GMED) reported fiscal 2026 Q2 results on Aug 06th, 2026, showing mixed signals between top-line growth and bottom-line pressure. While revenue increased 5.9% year-over-year, GAAP net income declined 25.3% largely due to a prior-year bargain purchase gain. However, non-GAAP EPS surged 55.8%, and the company raised its full-year EPS guidance significantly, reflecting strong underlying operational momentum and margin expansion.

Revenue

The total revenue of Globus Medical increased by 5.9% to $789.61 million in 2026 Q2, up from $745.34 million in 2025 Q2. Within this total, Musculoskeletal Solutions contributed the bulk of the performance with $763.54 million, while Enabling Technologies added $26.07 million, resulting in the reported Total net sales of $789.61 million.

Earnings/Net Income

Globus Medical's EPS declined 25.3% to $1.12 in 2026 Q2 from $1.50 in 2025 Q2. Meanwhile, the company's net income declined to $151.57 million in 2026 Q2, down 25.3% from $202.85 million reported in 2025 Q2. Remarkably, in 2026 Q2, the company set a new record high for fiscal Q2 net income, the highest in 16 years. Despite the GAAP decline driven by prior-year anomalies, the non-GAAP EPS of $1.34 represents a strong 55.8% increase, indicating robust core profitability.

Price Action

The stock price of Globus Medical has edged up 0.10% during the latest trading day, has edged up 1.02% during the most recent full trading week, and has edged up 2.85% month-to-date.

Post-Earnings Price Action Review

The analysis of Globus Medical’s recent earnings event reveals limitations in conducting a comprehensive backtest due to data constraints. Specifically, a true “buy on revenue beat, hold 30 days” strategy cannot be executed because the dataset lacks a verified revenue beat/miss label or consensus estimates for the earnings events. While it is possible to test the 30-day price reaction from the latest earnings close, this approach does not constitute a revenue-beat backtest unless the beat is confirmed. GMED’s latest earnings release was on August 6, 2026, with a closing price of $81.08. A clean 30-day test would compare this close to the price 30 trading days later; however, the dataset does not provide the price for that specific future date, preventing the computation of the full 30-day return. Consequently, the current analysis remains a single-event observation rather than a statistically significant backtest. If you want, I can run a real revenue-beat backtest across many stocks, not just GMED. For example, I can screen for stocks with revenue beat vs consensus, held for 30 trading days, and sorted by post-earnings 30-day return. That would give you a statistically meaningful result instead of a single-event observation. Are you trying to optimize this for maximum 30-day return, or for best risk-adjusted return—and do you want the backtest to include all revenue beats, or only large beats?

CEO Commentary

Keith Pfeil, President and Chief Executive Officer, highlighted sustained momentum with 6% overall revenue growth in Q2 2026, driven by share gains across underlying businesses. US Spine grew 7% and International Spine grew 14% as-reported, marking the fifth consecutive quarter of above-market growth for US Spine. Pfeil emphasized that the depth of the product portfolio and exclusive selling model position Globus to lead with innovation and commercial outreach. The leadership outlook is optimistic, focusing on long-term share growth through the Globus ecosystem. This strategy integrates patient selection, surgical techniques, implants, and technology into a closed-loop surgical intelligence ecosystem to improve surgical outcomes and drive performance.

Guidance

Globus Medical reaffirms its full-year 2026 revenue guidance at $3.18 billion to $3.22 billion. The company significantly updates its non-GAAP fully diluted EPS guidance upward to a range of $4.95 to $5.05, revised from the previous estimate of $4.70 to $4.80. This upward revision reflects disciplined execution, including margin expansion, operating leverage, and synergy realization from the Nevro acquisition. CFO Kyle Kline noted that adjusted gross margin expanded by 200 basis points year-over-year in Q2, contributing to record non-GAAP net income and EPS. The guidance underscores the company’s confidence in delivering sustained earnings growth and enhanced shareholder returns throughout the remainder of 2026, supported by broad-based product strength and improved profitability metrics.

Additional News

Globus Medical continues to strengthen its market position through strategic acquisitions and operational integration. The recent completion of the Nevro acquisition has been a focal point, with management highlighting synergy realization as a key driver for margin expansion and EPS growth in Q2 2026. This merger has allowed Globus to expand its product portfolio beyond traditional musculoskeletal solutions, integrating neurostimulation technologies that complement its spine and orthopedic offerings. The company has not announced any changes to its C-suite leadership or dividend policies during this period. Instead, the focus remains on executing the integration of Nevro’s assets to drive long-term value. Analysts are closely monitoring the post-merger performance, particularly regarding cross-selling opportunities and cost synergies. The successful realization of these synergies in Q2 has bolstered investor confidence, leading to the upward revision of full-year EPS guidance. This strategic move positions Globus as a more diversified leader in the medical device sector, enhancing its competitive moat against rivals.